Subjects are eligible for the study if all of the following apply: 1. All patients should be eligible for COVID-19 vaccination as described by the instructions of the manufacturer. 2. Age of 18 years or older 3. Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) 4. A diagnosis of either one of the IUIS criteria based diagnoses below: - CVID, with or without use of immunosuppressive therapy - CID - CGD - XLA - Selective IgG subclass deficiency - SADNI - Partners, sibling or other family member from patient (not suffering from a PID) Een van onderstaande diagnoses: CVID, met of zonder gebruik van afweeronderdrukkende medicatie immuunsuppresiva CID CGD XLA Selectieve IgG subklasse deficiëntie SADNI 18 jaar of ouder. In staat toestemming te geven

Subjects are eligible for the study if all of the following apply: 1. All patients should be eligible for COVID-19 vaccination as described by the instructions of the manufacturer. 2. Age of 18 years or older 3. Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) 4. A diagnosis of either one of the IUIS criteria based diagnoses below: - CVID, with or without use of immunosuppressive therapy - CID - CGD - XLA - Selective IgG subclass deficiency - SADNI - Partners, sibling or other family member from patient (not suffering from a PID) Een van onderstaande diagnoses: CVID, met of zonder gebruik van afweeronderdrukkende medicatie immuunsuppresiva CID CGD XLA Selectieve IgG subklasse deficiëntie SADNI 18 jaar of ouder. In staat toestemming te geven